Figure 5.

Pharmaceutical inhibition of spliceosome activity selectively reduces expression of fusion transcripts in neuroblastoma cells. (A, B) Splicing-dependent generation of several high frequent fusion transcripts in LAN-1 (A) and SK-N-BE(1) (B) neuroblastoma cells. SK-N-BE(1) and LAN1 cells were treated with splicing inhibitor Pladienolide B at 100 nM (SK-N-BE(1)) and 5–50 nM (LAN-1) for 6 h; RNA was isolated from harvested cells and reversely transcribed to cDNA; RT-PCR were performed with primers spanning the fusion junctions (fusion transcript) or exon–exon boundary (wild-type cognate).